CTT-1403 is under clinical development by Cancer Targeted Technology and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CTT-1403’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CTT-1403 overview

CTT-1403 is under development for the treatment of metastatic castration resistant prostate cancer. It is a phosphoramidate based drug containing an auxillary albumin binding motif. The drug candidate acts by targeting the cells expressing prostate-specific membrane antigen (PSMA) and specifically deliver a therapeutic dose of the radionuclide Lutetium-177 (177Lu).

Cancer Targeted Technology overview

Cancer Targeted Technology is a biotechnology company. The Company commercializes small molecule inhibitors to pivotal enzyme targets in cancer.It is headquartered in Woodinville, Washington, the US.

For a complete picture of CTT-1403’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.